Piper Sandler restated their overweight rating on shares of Replimune Group (NASDAQ:REPL – Get Rating) in a research note published on Monday morning, Benzinga reports. The firm currently has a $44.00 target price on the stock. A number of other brokerages have also commented on REPL. HC Wainwright boosted their price objective on Replimune Group […]
During the forecast period 2023 to 2033, the oncolytic adenovirus market is expected to grow at a value of 7.5% CAGR, according to Future Market Insights. By the year 2033, the global market for oncolytic adenovirus is expected to rise up to a market valuation of US$ 250 Billion. Growth of the market can be attribut.
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the […]